Kraków, Poland – 13 February 2017 – MNK1 and MNK2 are MAP kinase-interacting serine/threonine kinases, which are activated by RAS and MAPK signaling pathways and are involved in regulation of protein translation.

A growing number of reports on developments of novel, selective inhibitors of MNK1/2 kinases, has prompted a group of Selvita researchers to summarize the most important achievements and current challenges in a form of review.

The article “Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 And 2 (MNK1 And MNK2) As Targets For Cancer Therapy: Recent Progress In The Development Of MNK Inhibitors“, has been recently published in the Current Medicinal Chemistry journal: Volume 24, 42 Issues, 2017.